Stifel Reiterates Hold Rating on Fate Therapeutics (FATE)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to Stifel Reiterates Hold Rating on Fate Therapeutics (FATE)
November 18, 2024 11:22 AM EST
TD Cowen analyst Tara Bancroft reiterated a Hold rating on Fate Therapeutics (NASDAQ: FATE).
The analyst commented, "The first SLE patient treated with FT819 (iCAR-T) is now past 6 months with ongoing clinical remission, low disease activity, and resolution of key quality of life... More
November 18, 2024 8:05 AM EST
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented initial clinical and translational data from the first patient treated in its FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American College of Rheumatology (ACR) Convergence being held in Washington, D.C. The patient, a 27-year-old African American-Asian woman diagnosed with lupus nephritis (LN) over ten years ago, received fludarabine-free conditioning followed by a single dose of... More
